Skip to main content

Table 2 Baseline, 6-month and change in body composition and biochemical parameters over 6-months for study completers

From: Effects of recombinant human growth hormone (rhGH) administration on body composition and cardiovascular risk factors in obese adolescent girls

  

RhGH +

 

RhGH -

 
 

Baseline

6-month N = 5

6-month delta

Baseline

6-month N = 7

6-month delta

6 month delta P

Weight (kg)

99.9 ± 29.5

100.6 ± 30.9

0.7 ± 4.3

96.5 ± 18.1

100.4 ± 23.1

3.9 ± 6.6

0.81*

BMI (kg/m2)

39.6 ± 10.2

39.8 ± 10.8

0.2 ± 2.0

36.4 ± 7.3

37.8 ± 9.6

1.4 ± 2.5

0.81*

Waist circumference (cm)

115.4 ± 21.7

113.7 ± 23.1

-1.7 ± 4.0

112.4 ± 17.0

112.5 ± 21.2

0.1 ± 6.5

0.60

W/H ratio

0.94 ± 0.06

0.95 ± 0.06

0.003 ± 0.03

0.91 ± 0.08

0.91 ± 0.08

-0.005 ± 0.04

0.72

SAT (cm2)

578.5 ± 234.8

577.4 ± 232.9

-1.1 ± 60.8

570.0 ± 206.4

606.3 ± 231.1

36.3 ± 51.6 (N = 6)

0.30

VAT (cm2)

92.7 ± 36.6

93.3 ± 47.3

0.6 ± 29.9

90.4 ± 39.6

98.4 ± 43.5

8.0 ± 31.9 (N = 6)

0.70

TAT (cm2)

671.3 ± 264.1

670.7 ± 278.9

-0.5 ± 83.3

660.3 ± 209.1

704.6 ± 234.5

44.3 ± 63.1 (N = 6)

0.34

Thigh subcutaneous fat (cm2)

217.7 ± 72.1

208.7 ± 73.1

-9.0 ± 16.0

228.5 ± 103.4

211.2 ± 72.7

18.6 ± 29.0 (N = 6)

0.08*

Lean mass (grams)

50741.3 ± 7963.2

50758.1 ± 8735.6

17 ± 2160

50659.5 ± 7149.8

51360.7 ± 7309.6

701 ± 2325

0.62

IGF-1 (ng/mL)

235.4 ± 61.9

234.0 ± 48.5

-1.4 ± 79.4

266.0 ± 83.6

185.9 ± 58.0

-80.1 ± 48.8

0.06

2 HR-glucose (OGTT) (mg/dL)

119.8 ± 14.8

113.2 ± 17.6

-6.6 ± 17.0

112.7 ± 14.2

135.1 ± 23.7

22.4 ± 28.8

0.07

HbA1c (%)

5.62 ± 0.30

5.58 ± 0.16

-0.04 ± 0.17

5.47 ± 0.25

5.61 ± 0.30

0.14 ± 0.08

0.03

Insulin uU/mL

25.4 ± 25.7

22.6 ± 17.8

-2.8 ± 11.7

41.9 ± 41.0

27.1 ± 22.5

-14.8 ± 38.3

0.94*

Total cholesterol (mg/dL)

189.2 ± 42.6

151.4 ± 27.8

-37.8 ± 23.9

162.1 ± 39.7

153.6 ± 34.8

-8.6 ± 15.5

0.03

LDL (mg/dL)

121.2 ± 27.7

95.4 ± 22.4

-25.8 ± 12.8

98.3 ± 35.8

87.6 ± 28.0

-10.7 ± 11.9

0.06

HDL (mg/dL)

48.2 ± 13.4

41.6 ± 8.2

-6.6 ± 6.1

44.0 ± 7.4

45.0 ± 5.2

1.0 ± 5.1

0.04

VLDL (mg/dL)

19.8 ± 11.2

14.4 ± 6.0

-5.4 ± 9.6

19.9 ± 7.0

21.0 ± 16.3

1.1 ± 11.7

0.48*

Triglycerides (mg/dL)

99.4 ± 55.7

71.6 ± 29.5

-27.8 ± 46.8

99.1 ± 35.5

105.3 ± 24.9

6.1 ± 58.4

0.57*

hsCRP (mg/L)

3.5 ± 2.1

2.69 ± 1.8

-0.77 ± 2.36

4.4 ± 3.8

4.27 ± 4.6

-0.09 ± 1.79

0.58

sICAM-1 (ng/mL)

226.4 ± 79.3

204.2 ± 74.5

-22.2 ± 30.3

241.1 ± 48.1

262.2 ± 74.8

21.1 ± 33.3

0.04

  1. *Wilcoxon rank sum test.
  2. HbA1c, Total Cholesterol, HDL and sICAM were lower after 6 months of rhGH + treatment.
  3. RhGH+: Group that received rhGH; RhGH-: Group that received placebo/no treatment.
  4. Baseline: Mean Baseline values only for study completers.
  5. 6-month: Mean 6-month values for study completers.
  6. 6-month delta: Change over 6-months from Mean Baseline to Mean 6-month values.
  7. Abbreviations: BMI body mass index, BMI SDS body mass index standard deviation score, HbA1c hemoglobin A1c, HDL high density lipoprotein, hsCRP high sensitivity C-reactive protein, IGF-1 insulin like growth factor-1, LDL low density lipoprotein, OGTT oral glucose tolerance test, SAT subcutaneous adipose tissue, sICAM-1 soluble intercellular adhesion molecule 1, TAT, VAT total, visceral adipose tissue, VLDL very low density lipoprotein, W/H waist to hip ratio.